The pathophysiologic pathways that govern the development of choroidal neovascularization (CNV) are complex. Patchy atrophy and lacquer cracks are known to be major anatomic risk factors for the development of myopic CNV, but they are not alone and much remains to be understood about other factors that influence development. In addition, a greater understanding of the modifiable and nonmodifiable factors that influence outcome, resolution, and recurrence after intravitreal injection of anti-vascular endothelial growth factor (VEGF) could lead to more personalized treatment algorithms that integrate parameters other than the presence of CNV itself and could help improve clinical outcomes and reduce recurrence.
Methods
We reviewed recently published data on risk factors for CNV and predictors of response to anti-VEGF treatments. In particular, data pertaining to age, sex, genetic predisposition, baseline visual acuity, axial length, staphyloma, lacquer cracks, atrophic lesions, choroidal thickness or choroidal thinning, characteristics of CNV such as duration, localization, and size of CNV, and treatment considerations such as choice of treatment, loading doses, and combination treatments were reviewed.
Results
Our analysis showed that the body of evidence is incomplete.
Conclusions
Additional studies are required to identify high-risk patients and to develop personalized therapeutic approaches.
GrossniklausHEGreenWRPathologic findings in pathologic myopia. Retina. 1992;12(2):127–133
2.
Ohno-MatsuiKYoshidaTFutagamiSPatchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003;87(5):570–573
3.
HayashiKOhno-MatsuiKShimadaNLong-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology. 2010;117(8):15951611.e1-1611.e4.
4.
NeelamKCheungCMOhno-MatsuiKLaiTYWongTYChoroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495–525
5.
ShinYJNamWHParkSEKimJHKimHKAqueous humor concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in high myopic patients. Mol Vis. 2012;18:2265–2270
6.
TongJPChanWMLiuDTAqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456–462
7.
AhnSJWooSJKimKEParkKHAssociation between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54(3):2115–2122
8.
YoonJUKimYMLeeSJByunYJKohHJPrognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Retina. 2012;32(5):949–955
9.
WolfSBalciunieneVJLaganovskaGet al;RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682–92e2
10.
TufailANarendranNPatelPJRanibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944–5e1
11.
Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131(5):541–560
12.
Ruiz-MorenoJMAriasLMonteroJACarneiroASilvaRIntravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol. 2013;97(11):1447–1450
13.
WakabayashiTIkunoYChoroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol. 2010;94(5):611–615
14.
LevezielNCaillauxVBastuji-GarinSZmudaMSouiedEHAngiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol. 2013;155(5):913–919
15.
KojimaAOhno-MatsuiKTeramukaiSEstimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2006;244(11):1474–1479
KangHMKohHJOcular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study. Retina. 2013;33(8):1613–1622
18.
NakanishiHTsujikawaAYodoiYPrognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond). 2011;25(3):375–381
19.
WangJKangZSummary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol. 2012;250(12):1717–1723
20.
YangHSKimJGKimJTJoeSGPrognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013;156(6):1201–1210e2
21.
KobayashiKMandaiMSuzumaIKobayashiHOkinamiSExpression of estrogen receptor in the choroidal neovascular membranes in highly myopic eyes. Retina. 2002;22(4):418–422
22.
Ghaem-MaghamiSCookHBirdAWilliamsDHigh myopia and pre-eclampsia: a blinding combination. BJOG. 2006;113(5):608–609
23.
IntroiniUCasalinoGCardaniAIntravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. J Ocul Pharmacol Ther. 2012;28(5):553–555
24.
LevezielNYuYReynoldsRGenetic factors for choroidal neovascularization associated with high myopia. Invest Ophthalmol Vis Sci. 2012;53(8):5004–5009
25.
MiyakeMYamashiroKNakanishiHEvaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci. 2013;54(6):4208–4212
26.
Akagi-KurashigeYKumagaiKYamashiroKVascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci. 2012;53(4):2349–2353
27.
FagernessJAMallerJBNealeBMReynoldsRCDalyMJSeddonJMVariation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet. 2009;17(1):100–104
28.
International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789–796
29.
ParmeggianiFGemmatiDCostagliolaCImpact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia. Ophthalmology. 2010;117(3):517–523
30.
MiyakeMYamashiroKAkagi-KurashigeYVascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology. 2014;121(1):225–233
31.
IkunoYJoYHamasakiTTanoYOcular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci. 2010;51(7):3721–3725
32.
SakaNMoriyamaMShimadaNChanges of axial length measured by IOL master during 2 years in eyes of adults with pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2013;251(2):495–499
33.
TakahashiAItoYIguchiYYasumaTRIshikawaKTerasakiHAxial length increases and related changes in highly myopic normal eyes with myopic complications in fellow eyes. Retina. 2012;32(1):127–133
34.
HayashiKOhno-MatsuiKYoshidaTCharacteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):13–19
35.
CurtinBJThe posterior staphyloma of pathologic myopia. Trans Am Ophthalmol Soc. 1977;75:67–86
36.
HsiangHWOhno-MatsuiKShimadaNClinical characteristics of posterior staphyloma in eyes with pathologic myopia. Am J Ophthalmol. 2008;146(1):102–110
37.
SteidlSMPruettRCMacular complications associated with posterior staphyloma. Am J Ophthalmol. 1997;123(2):181–187
38.
IkunoYSayanagiKSogaKLacquer crack formation and choroidal neovascularization in pathologic myopia. Retina. 2008;28(8):1124–1131
39.
NishidaYFujiwaraTImamuraYLimaLHKurosakaDSpaideRFChoroidal thickness and visual acuity in highly myopic eyes. Retina. 2012;32(7):1229–1236
40.
HarbEHymanLGwiazdaJet al;COMET Study Group. Choroidal thickness profiles in myopic eyes of young adults in the Correction of Myopia Evaluation Trial cohort. Am J Ophthalmol. 2015;160(1):62–71e2
41.
RegatieriCVBranchiniLFujimotoJGDukerJSChoroidal imaging using spectral-domain optical coherence tomography. Retina. 2012;32(5):865–876
42.
HayashiKShimadaNMoriyamaMHayashiWTokoroTOhno-MatsuiKTwo-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia. Retina. 2012;32(4):687–695
43.
IkunoYSayanagiKSogaKIntravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147(1):94–100e1
44.
LaiTYLukFOLeeGKLamDSLong-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26(7):1004–1011
45.
WangEChenYIntravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina. 2013;33(7):1375–1392
46.
Ruiz-MorenoJMGomez-UllaFMonteroJAIntravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye (Lond). 2009;23(2):334–338
47.
VoykovBGeliskenFInhoffenWVoelkerMBartz-SchmidtKUZiemssenFBevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?Graefes Arch Clin Exp Ophthalmol. 2010;248(4):543–550
48.
Ruiz-MorenoJMMonteroJAGomez-UllaFAresSIntravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol. 2009;93(4):448–451
